Pulmonary Therapy 2018回顾和2019展望说明书

PulmTher(2019)5:1–3

/10.1007/s41030-019-0085-y

EDITORIAL

PulmonaryTherapy:LookingBackon2018

andForwardto2019

Kai-MichaelBeeh

Received:January9,2019/Publishedonline:January17,2019

ÓTheAuthor(s)2019

DearReaders,

AswereflectonPulmonaryTherapy’ssuccessesin

2018andanticipateanotherrewardingyearfor

thejournalin2019,itisimportantto

acknowledgethetremendoussupportfromour

authors,readers,reviewers,Editorial,andAdvi-

rnalwouldnotoperate

withouttheculminationofthesegroupsandso

forthiswearetrulygrateful.

ThankyoutoallofourEditorialBoard

memberswhoareresponsibleforassistingthe

in-houseeditorialteam,contributingtheirown

research,suggestingreviewtopics,andgener-

allysupportingthejournalinitsdevelopment.

ThankyoualsotoourAdvisoryBoardwhoare

primarilyresponsibleforprovidingpeer-review

pportallowsustomaintain

ourrapidpublicationtimelinesandpublish

course,wemustthankallofourreviewerswho

werewardwithafreepublication(pendingpeer

review)foreverythreereviewscompletedper

etelistofourcurrent

EditorialandAdvisoryBoardmemberscanbe

foundhere.

EnhanceddigitalfeaturesToviewenhanceddigital

featuresforthisarticlegoto:/10.6084/

m9.figshare.7564919.

K.-(&)

insafRespiratoryResearchInstitute,Wiesbaden,

Germany

e-mail:******************

In2018,totaldownloadsacrossallpublica-

tionswasover67,themosthighly

readarticleswithin2018included:

•Improvingtheefficiencyofrespiratorydrug

delivery:areviewofcurrenttreatmenttrends

andfuturestrategiesforasthmaandchronic

uki,A.

&Agu,:///10.1007/s41030-

tivereviewarticlewith

over12,000downloadstodate.

•Theroleofthebodyclockinasthmaand

COPD:-

wiak,K.&Durrington,:///

10.1007/tive

reviewarticlewith4500downloadsanda

notablyhighnumberofsharesthrough

socialmediatodateat71.

•Identifyingcriticalerrors:addressinginhaler

techniqueinthecontextofasthmamanage-

-Anticevich,S.Z.,Cvetkovski,

B.,Azzi,:///10.1007/

tivereviewarti-

clewrittenbyourEditorialBoardmember

SinthiaBosnic-Anticevich,whichhasover

900downloadstodate.

•Anetworkmeta-analysisoflong-actingmus-

carinicantagonist(LAMA)andlong-acting

b2-agonist(LABA)combinationsinCOPD.

Sion,K.Y.J.,Huisman,E.L.,Punekar,.

/10.1007/s41030-017-0048-0.

Anoriginalresearcharticlewithover13,000

downloadsand5citationstodate.

2

PulmTher(2019)5:1–3

Real-worldpracticepatternsforprevention

andmanagementofpotentialadverseevents

withpirfenidoneinpatientswithidiopathic

pulmonaryfi,M.L.,Haselk-

orn,T.,Limb,:///10.

1007/-worldorigi-

nalresearcharticlewithover5400down-

loadstodate.

Wearereallypleasedtobepublishingmore

enhanceddigitalcontentsuchasvideosand

eer-reviewedfeaturesaccom-

panythemainarticleandaredesignedto

increasetheeducationalvalueofthecontent.

WehavealsobegunpublishingoptionalPlain

LanguageSummariesalongsidethestandard

abstracttoaidunderstandingandincreasedis-

seminationofresearchtonon-experts,includ-

ingnon-specialists,patients,caregivers,and

plefromWencel,MLetal.’s

originalresearcharticle,publishedearlierthis

year,canbefound/

medicine/internal/journal/41030?detailsPage=

editorialBoard.

In2018,thejournallaunchedanewtopical

collection‘‘PatientandPhysicianPerspectives’’.

Inlightofthegrowingsupportforgreater

patientinvolvement,thesecommentaryarticles

areco-authoredbyapatientandaphysician.

Thefirsthalfofthearticle,authoredbythe

patient,describestheirexperienceoflivingwith

ondhalfis

authoredbyeitherthepatient’streatingphysi-

cianoraphysicianwithexperiencetreating

sicianwillcomment

ontheseexperienceswithreferencetothe

ishedourfirst

articleinthisserieslastyearwithmoretofollow

lectioncanbefound

/journal/41030/topicalCollec

tion/AC_450cc146be7a92bfec5f45e7ab9e7737.

Lookingaheadto2019,wehopetosee

reportsofmanyinterestingandimportant

developmentsinthefieldofpulmonaryther-

elGlobalInitiativeforChronic

ObstructiveLungDisease(GOLD)2019strategy

hassuggestednovelpathwaysforpatientesca-

wemovetowardsamoreprecision-based

approachtomanagementofCOPD,wehopeto

seemoreprospectivetrialsorposthocanalyses

•

tofurtherinformthesepathwaysandaddevi-

dence,astowhichextentpatientfeaturesor

,eosinophils,can

clinical

dataonvariousinhalercombinations(dual

LABA/LAMAcombinationsaswellasfixeddose

‘‘triple’’LABA/LAMA/ICS)willbepublishedin

theupcomingyear,itmaybecomeeasiertoget

amoreconsistentpictureoftherelativeefficacy

ofthesedifferentcombinations,eveninthe

mayalsoincludemore‘‘real-world’’dataonthe

performanceofdifferentinhalerdevicesor

posologiesineverydayclinicalpracticeandthe

tion,

add-onstrategiesbeyondLAMA/LABA/ICS

inhalertherapyforpatientswithmoresevere

diseaseareeagerlyawaited,andmanyregistered

studiesarealreadyunderwayorawaitactivation

ofrecruitment.

Likewiseinasthma,weawaitmoreclinical

informationondifferenttargetedtherapies,

withmarketintroductionofonemore‘‘type2’’

drug(dupilumab;antiIL-4/IL-13receptor

blockage)pendinginmanyEuropeancountries,

andaplethoraofpipelinemoleculesunder

tdoubt,asthma

managementpathways,inparticularinsevere

patients,willverysoonentertheageof‘‘switch-

or-cycle’’algorithms,comparabletootherther-

,rheumatoidarthritis.

However,alongroadmustbetraveledbefore

firmevidence-basedconclusionscanbedrawn

aboutthequestionofwhichindividualpatient

‘‘trait’’isthemostattractivetargetforany

lapofthese

traitsaremoregeneralrulethanexceptionin

mostpatients,‘‘trial-and-error’’andindividual

preferenceswilllikelyhaveamajorimpacton

eless,eventhe

longestjourneystartswiththefirststep—sowe

shouldnotshyawayfromaddressingthese

importantquestionsatanearlystage!

Ininterstitiallungdisease(ILD),itwillbe

interestingtoobserveifthesmallbudsofther-

apeutichopeforpatientsaffectedbythe‘‘idio-

pathic’’formcanalsobeofferedforpatients

withotherformsoflungfi,autoim-

salso

muchtolearnaboutnewandvalidclinical

PulmTher(2019)5:1–3

3

tools,includingbiomarkers,indicatorsofpro-

gression,andpatient-reportedoutcomes,to

specificallyaddresstheneedsofpatientsaffec-

tedbyfieapplies

tomanyother—incomparisontoCOPDand

asthmaoftenneglected—respiratoryconditions

withgreatimportancetophysicians’everyday

work,includingbronchiectasis,lunginfections,

orthestillenigmaticchallengeofchronic

smisalwaysjustified,butmuch

workliesahead!

Finally,weinviteourreaderstoconsider

discussed,thereareanumberofexciting

developmentsinthefield,onwhichwelook

forwardtopublishingin2019.

Kai-MichaelBeeh,Editor-in-Chief

onalpaymentswere

receivedfromanypharmaceuticalentityinthe

titutionIrepresenthas

receivedcompensationforservicesonadvisory

boardsorconsultingforAblynx,Almirall,

AstraZeneca,BerlinChemie,Boehringer,Chiesi,

Cytos,Mundipharma,Novartis,PohlBoskamp,

titutionIrepresenthas

receivedcompensationforspeakeractivitiesin

scientificmeetingssupportedbyAlmirall,

AstraZeneca,BerlinChemie,Boehringer,Cytos,

ERT,GSK,Novartis,Pfizer,PohlBoskamp,and

titutionhasfurtherreceived

compensationfordesignandperformanceof

clinicaltrialsfromAlmirall,Altana/Nycomed,

AstraZeneca,Boehringer,Cytos,GSK,Infinity,

Medapharma,MSD,Mundipharma,Novartis,

Parexel,PearlTherapeutics,Pfizer,Teva,Sterna,

andZentiva.

articleisbasedonpreviouslyconductedstudies

anddoesnotcontainanystudieswithhuman

participantsoranimalsperformedbyanyofthe

authors.

ticleisdistributed

underthetermsoftheCreativeCommons

Attribution-NonCommercial4.0International

License(/licenses/

by-nc/4.0/),whichpermitsanynoncommercial

use,distribution,andreproductioninany

medium,providedyougiveappropriatecreditto

theoriginalauthor(s)andthesource,providea

linktotheCreativeCommonslicense,and

indicateifchangesweremade.

ACKNOWLEDGEMENTS

note,contrarytothe

journal’sstandardsingle-blindpeer-reviewpro-

cess,asaneditorialwrittenbytheEditor-in-

Chiefofthejournalthisarticlewasnotpeer

reviewed.

ingorsponsorshipwas

receivedforthisstudyorpublicationofthis

article.

edauthorsmeetthe

InternationalCommitteeofMedicalJournal

Editors(ICMJE)criteriaforauthorshipforthis

article,takeresponsibilityfortheintegrityof

theworkasawhole,andhavegiventheir

approvalforthisversiontobepublished.